Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 6/2012

01-06-2012 | Case Report

Good clinical response to methotrexate treatment in a patient with fibroblastic rheumatism

Authors: Juliane Aline Paupitz, Jozélio Freire de Carvalho

Published in: Rheumatology International | Issue 6/2012

Login to get access

Abstract

Fibroblastic rheumatism (FR) is a rare disease first described by Chaouat (in Rev Rhum Mal Osteoartic 47:345–351, 1980) and is characterized by a combination of rheumatologic and dermatological manifestations. Rheumatologic features are symmetrical polyarthralgias with joint stiffness, associated with cutaneous nodules and sclerodactyly. Histology shows an increased number of fibroblasts and a marked dermal fibrosis. A large number of treatments have been tried, but all of them have shown an unpredictable effect on FR. We report a Brazilian case of FR showing a good clinical response to methotrexate treatment. This drug may be considered an effective treatment in FR.
Literature
1.
Chaouat Y, Aron-Brunetiere R, Faures B et al (1980) Une nouvelle entité: le rhumatisme fibroblastique. A propos d’une observation. Rev Rhum Mal Osteoartic 47:345–351
2.
Vittecoq O, Mejjad O, da Silva F et al (1996) Preliminary experience with low-dose methotrexate in fibroblastic rheumatism. Arthritis Rheum 39:2070–2073PubMedCrossRef
3.
4.
Réty F, Tayebjee OA, Servettaz A et al (2007) Radiological bone lesions in fibroblastic rheumatism; case report. Press Med 36:432–436CrossRef
5.
Fam AG, Hanna W, Mak V et al (1998) Fibroblastic rheumatism: clinical and histologic evolution of cutaneous manifestations. J Rheumatol 25:2261–2266PubMed
6.
Lee JM, Sundel RP, Liang MG (2002) Fibroblastic rheumatism: case report and review of the literature. Pediatr Dermatol 20:461–462
7.
Cantwell AR Jr, Rowe L, Kelso DW (1980) Nodular sclerodermanad pleomorphic acid-fast bacteria. Arch Dermatol 116:1283–1290PubMedCrossRef
8.
Fortirer-Beaulieu M, Thomine E, Boullie MC et al (1993) New electron microscopic findings in a case of multicentric reticulohistiocytosis. Am J Dermatopathol 15:587–589CrossRef
9.
Schiavon F, Punzi L, Todesco S (1998) Fibroblastic rheumatism: a fifteen-year followup study. Arthritis Rheum 41:759–760PubMedCrossRef
10.
Collona L, Barbieri C, Di Lella G et al (2002) Fibroblastic rheumatism: a case without rheumatological symptoms. Acta Derm Venereol 82:200–203CrossRef
11.
Ostlere LS, Stevens HP, Jarmulowicz M (1994) Fibroblastic rheumatism. Clin Exp Dermatol 19:268–270PubMedCrossRef
12.
Crouzet J, Amouroux M, Duterque N et al (1982) Rhumatisme Fibroblastique: un cas avec étude de l′histologie synoviale. Rev Rhum Mal Osteoartic 49:469–472PubMed
13.
Meyer FA, Yaron I, Mashiah V et al (1993) Methotrexate inhibits proliferation but not interleukin 1 stimulated secretory activities of cultured human synovial fibroblasts. J Rheumatol 20:238–242PubMed
14.
Haraoui B, Pelletier J-P, Cloutier J-M et al (1991) Synovial membrane histology nad immunopathology in rheumatoid arthritis and osteoarthritis: in vivo effect of antirheumatic drugs. Arthritis Rheum 34:153–163PubMedCrossRef
Metadata
Title
Good clinical response to methotrexate treatment in a patient with fibroblastic rheumatism
Authors
Juliane Aline Paupitz
Jozélio Freire de Carvalho
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 6/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1433-2

Other articles of this Issue 6/2012

Rheumatology International 6/2012 Go to the issue

Erratum

Erratum to: The prevalence of medical nomadism of the followed patients in rheumatology

Original Article

Extraarticular manifestations in Turkish patients with rheumatoid arthritis: impact of EAMs on the health-related quality of life in terms of disease activity, functional status, severity of pain, and social and emotional functioning

Case Report

Intracranial manifestations in SAPHO syndrome: the first case report in literature

Letter to the Editor

Recurrence of severe low back pain due to myeloproliferative disorder in a patient affected by seronegative spondyloarthropathy

Case Report

Coexisting Behçet’s disease and ankylosing spondylitis presented with deep venous thrombosis: a case report and review of the literature

Original Article

Role of matrix metalloproteinase-3 (MMP-3) and magnetic resonance imaging of sacroiliitis in assessing disease activity in ankylosing spondylitis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits